Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

Executive Summary

Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.


Related Content

Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses
Morphosys Seeks US Listing To Cement Corporate Developments
Finance Watch: Despite Bad News, IPOs And Public Offerings Keep Flowing
Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends
IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns
IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
Mereo On The Move With Strong COPD Data And US Listing Plan
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Novartis Bolsters I-O Discovery Pipeline With Surface Oncology Deal
FUNDING ROUNDUP: One startup, six public companies raise cash


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts